Antiphospholipid Syndrome In Pregnancy

Title: Antiphospholipid Syndrome In Pregnancy

Authors: Dr Arati Nayak, Dr Arata Kumar Swain, Dr Pradipta Kumar Patel, Dr Harekrusna Dalai

DOI: http://dx.doi.org/10.18535/jmscr/v4i1.08

Abstract

The antiphospholipid syndrome (APS) is a multisystemic disease, characterized by venous or arterial thromboses, or certain obstetric complications, and the presence of antiphospholipid antibodies (APAs) ^(1-4).

Lupus anticoagulant (LA), anticardiolipin antibodies (aCL) and anti-beta 2 glycoprotein 1 (anti-β2GP1) antibodies are the main antibodies in this syndrome (1;2;) APS occurs in isolation as a primary APS in more than 50% of the cases, but can be associated with other autoimmune diseases, most often with systemic lupus erythemathosus (SLE). Twenty to 35% of women with SLE develop APS ⁽⁶⁾. APS occurs for the most part in young women of fertile age ⁽⁷⁾. The most characteristic feature of obstetrical APS is miscarriage, It occurs rarely in children, and only 12% of all APS occur after 50 years of age⁽⁸⁾

References

1. de LB, Mertens K, de Groot PG. Mechanisms of disease: antiphospholipid antibodiesfrom clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 2008 Apr;4(4):192-9.

2. Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis,management, and controversies. Obstet Gynecol 2003 Jun;101(6):1333-44.

3. Ahmed K, Darakhshan A, Au E, Khamashta MA, Katsoulis IE. Postpartum spontaneous colonic perforation due to antiphospholipid syndrome. World J Gastroenterol 2009 Jan 28;15(4):502-5.

4. Carp HJ. Antiphospholipid syndrome in pregnancy. Curr Opin Obstet Gynecol 2004 Apr;16(2):129-35.

5. do Prado AD, Piovesan DM, Staub HL, Horta BL. Association of anticardiolipin antibodies with preeclampsia: a systematic review and meta-analysis. Obstet & Gynecol 2010 Dec;116(6):1433-43.

6. Tincani A, Andreoli L, Chighizola C, Meroni PL. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity 2009 May;42(4):257-9

7. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 Feb;4(2):295-306.)

8. Cohen D, Berger SP, Steup-Beekman GM, Bloemenkamp KW, Bajema IM. Diagnosis and management of the antiphospholipid syndrome. BMJ 2010;340:c2541.

9. Cervera R, Piette J C, Font J, Khamashta M A, Shoenfeld Y, Camps M T. et al Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 2002 461019–1027.1027 [PubMed]

10. Cervera R, Balasch J. The management of pregnant patients with antiphospholipid syndrome. Lupus200413683–687.687 [PubMed]

11. Branch D W, Khamashta M A. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol 20031011333–1344.1344 [PubMed]

12. Carmona F, Balasch J. Fetal and obstetric manifestations and infertility in the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette, Shoenfeld Y, eds. The antiphospholipide syndrome II: autoimmune thrombosis Amsterdam: Elsevier, 2000205–211.211

Asherson R A. The catastrophic antiphospholipid syndrome. J Rheumatol 199219508–512.512 [PubMed]

13. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006 Feb;4(2):295-306

14. Si-Hoe CK, Thng CH, Chee SG, Teo EK, Chng HH. Abdominal computed tomo-graphy in systemic lupus erythematosus. Clin Radiol 1997 Apr;52(4):284-9.

15. Brey RL. Antiphospholipid antibodies in young adults with stroke. J Thromb Thrombolysis 2005 Oct;20(2):105-1218] Raval M, Paul A. Cerebral Venous Thrombosis and Venous Infarction: Case Report of a Rare Initial Presentation of Smoker's Polycythemia. Case Rep Neurol 2010;2(3):150-6

16. Csepany T, Bereczki D, Kollar J, Sikula J, Kiss E, Csiba L. MRI findings in central nervous system systemic lupus erythematosus are associated with immunoserological parameters and hypertension. J Neurol 2003 Nov; 250(11):1348-54..

17. Ringrose DK. Anaesthesia and antiphospholipid syndrome – a review of 20 patients. Int J Obstet Anaesth 1997;6: 107–111.

18. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002;346:752–763.

19. Julkunen H. Pregnancy in systemic lupus erythematosus. Contraception, fetal outcome and congenitalheart block. Acta Obst Gynecol Scand 1994;73:517–520.

20. MacLean M, Cumming G, McCall F, Walker I, Walker J. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994;101:103–106.

21. Silver RM, Branch DW. Recurrent miscarriage: autoimmune considerations. Clin Obstet Gynaecol1994;37:745–760.

22. Rai RS, Clifford K, Cohen H, Regan L. High prospective fetal loss rate in untreated pregnancies of women with recurrent miscarriage and antiphospholipid antibodies. Hum Reprod 1995;10:3301–3304.,.

23. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC. The prevalence and biologic significance of lupus anticoagulant and anticardiolipin in a general obstetric population. Am J Obstet Gynecol 1989;161:369–373.

24. Perez MC, Wilson WA, Brown HL, Scopelitis E. Anti-cardiolipin antibodies in unselected pregnant women in relationship to fetal outcome. J Perinatol 1991;11:33–36

25. Branch DW, Scott JR, Kochenour NK. Obstetric complications associated with lupus anticoagulant.N Engl J Med 1985;313:1322–1326.

26. Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisolone suppression of maternal lupus anticoa-gulant. Lancet 1983;i:1361–1363.,

27. Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GRV. Thrombosis, recurrent fetalloss and thrombocytopenia. Predictive value of the anticardiolpin antibody test. Arch Intern Med1986;146:2153–2156.

28. Reece EA, Garofalo J, Zheng XZ, Assimakopoulos E. Pregnancy outcome – influence of antiphospholipid antibody titer, prior pregnancy loss and treatment. J Reprod Med 1997;42:49–55.,

29. Lynch A, Marlar R, Murphy J, et al. Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 1994;120:470–475..

30. Katano K, Aoki K, Ogasawara M, et al. Specific ntiphospholipid antibodies (aPL) eluted from placentae of pregnant women with aPL-positive sera. Lupus 1995;4:304–308.,

31. Buchanan NMM, Khamashta MA, Morton KE, Kerslake S, Baguley E, Hughes GRV. A study of 100 high risk lupus pregnancies. Am J Rep Immunol 1992;28:192–194.

32. Ramsey-Goldman R, Mientus JM, Kutzer JE, Mulvihill JJ, Medsger JTA. Pregnancy outcome inwomen with systemic lupus erythematosus treated with immune-suppressive drugs. J Rheumatol 1993;20:1152–1157..

33. Branch DW, Andres R, Digre KB, Rote NS, Scott JR. The association of antiphospholipid antibodies with severe pre-eclampsia. Obstet Gynecol 1988;73:541–545.

34. Moodley J, Bhoola V, Duursma J, Pudifin D, Byrne S, Kenoyer DG. The association of antiphospholipid antibodies with severe early-onset pre-eclampsia. South African Med J 1995;85:105–107.

35. Yasuda M, Takakuwa K, Tanaka K. Studies on the association between the anticardiolipin antibody and pre-eclampsia. Acta Med Biol 1994;42:145–149.

36. Dekker GA, de Vries JIP, Doelitzsch PM, et al. Underlying disorders associated with severe earlyonset preeclampsia. Am J Obstet Gynecol 1995;173:1042–1048

37. Birdsall MA, Pattison NS, Chamley L. Antiphospholipid antibodies in pregnancy. Aust N Z J Obstet Gynecol 1992;32:328–330., and premature delivery [29, 30] 47. Kelly T, Whittle MJ, Smith DJ, Ryan G. Lupus anticoagulant and pregnancy. J Obstet Gynecol1996;16:26–31.

38. Botet F, Romera G, Montagut P, Carmona F, Balasch J. Neonatal outcome in women treated for the antiphospholipid syndrome during pregnancy. J Perinat Med 1997;25:192–196..

39. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR. Outcome of treated pregnancies in women with antiphos-pholipid syndrome: an update of the Utah experience. Obstet Gynecol 1992;80:614–620.,

40. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus 1997;6:509–513.

41. Backos M, Rai R, Baxter N, Chilcott I T, Cohen H, Regan L. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin. Br J Obstet Gynaecol 1999;106:102–107..

42. Cowchock FS. Autoantibodies and pregnancy loss. N Engl J Med 1997;337:197–198..

43. Empsom M, Lassere M, Craig JC, Scott JR. Recurrent pregnancy loss with antiphospholipid antibody:a systematic review of therapeutic trials. Obstet Gynecol 2002;99:135–144..

44. Silver R, MacGregor SN, Sholl JS, Hobart JM, Neerhof MG, Ragin A. Comparative trial of prednisolone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody positiveobstetric patients. Am J Obstet Gynecol 1993;169:1411–1417.

45. Balasch J, Carmona F, Lopez-Soto A, et al owchock S, Reece EA. Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Am J Obstet Gynecol 1997;176:1099–1100..

46. Yu CK, Papageorghiou AT, Parra M, Palma Dias R, Nicolaides KH. Randomized controlled trialusing low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks’ gestation. Ultrasound Obstet Gynecol 2003;22:233–239.

47. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomised trial comparing prednisolone with low dose heparin treatment. Am J Obstet Gynecol 1992;166:1318–1323..

48. Ruffati A, Orsini A, Di Lenardo L, et al

49. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss–treatment withheparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996;174:1584–1589.

50. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (orantiphos-pholipid ntibodies). Br Med J 1997; 314:253–257., although not all studies have shown a benefit in this subgroup

51. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized,controlled trial of treatment. Obstet Gynecol 2002;100:408–413.

52. de Swiet M, Ward PD, Fidler J, et al. Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 1983;90:1129–1134.

53. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancyand the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J ObstetGynecol 1993;168:1265–1270.

54. Nelson-Piercy C, Letsky E, de Swiet M. Low molecular weight heparin for obstetric thromboprophylaxis: experience of 69 pregnancies in 61 high risk women. Am J Obstet Gynecol1997;176:1062–1068..

55. Smith R, Stevenson JC, Winearls CG, Woods CG, Wordsworth BP. Osteoporosis of pregnancy. Lancet 1985;1:1178–1180.

56. Khastgir G, Studd J. Pregnancy-associated osteoporosis. Br J Obstet Gynaecol 1994;101:836–838.

57. Smith R, Athanasou NA, Ostlere SJ, Vipond SE. Pregnancy-associated osteoporosis. QJM 1995;88:865–878..

58. Nelson-Piercy C. Heparin-induced osteoporosis in pregnancy. Lupus 1997;6:500–504.

59. Greer IA, Nelson-Piercy C. Systematic review of safety and efficacy of LMWH in pregnancy. Br J Obstet Gynaecol 2004. In press.. Although Factor Xa levels may be used to monitor LMWH [67] 67. Hunt BJ, Doughty H, Majumdar G, et al.

60. Hunt BJ, Khamashta MA, Lakasing L, Williams F, Nelson-Piercy C, Hughes GRV. Thromboprophylaxis in antiphos-pholipid syndrome pregnancies with previous cerebral arterialthrombotic events: is warfarin preferable? Thromb Haemost 1998;79:1060–1061..

61. Nelson-Piercy C. Low molecular weight heparin for obstetric thromboprophylaxis. Br J Obstet Gynaecol 1994;101:6–8..

62. Shaul WL, Hall JG. Multiple congenital anomalies associated with oral anticoagulants. Am J Obstet

Gynecol 1977;127:191–198..

63. Ginsberg JS, Hirsh J, Turner DC, Levine MN, Burrows R. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989;61:197–203.,

64. Vitale N, Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999;33:1637–1641.

65. Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002;99:35–40..

66. Kwak JYH, Barini R, Gilman-Sachs A, Beaman KD, Beer AE. Down-regulation of maternalantiphospholipid antibodies during early pregnancy and pregnancy outcome. Am J Obstet Gynecol 1994; 171:239–246.

67. Laskin CA, Bombardier C, Hannah ME, et al. Prednisolone and aspirin in women with autoantibodies and unexplained recurrent fetal loss. N Engl J Med 1997;337:148–153..

68. Spinnato JA, Clark AL, Pierangeli SS, Harris EN. Intravenous immunoglobulin therapy for the antiphospholipid syndrome in pregnancy. Am J Obstet Gynecol 1995;172:690–694.

69. Kaaja R, Julkunen H, Ammala P, Palouso T, Kurki P. Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy losses associated ithntiphospholipid antibodies.Acta Obstet Gynaecol Scand 1993;72:63–66.

70. Arnout J, Spitz B, Wittevrongel C, Vanrusselt M, Van Assche A, Vermylen J. High-dose intravenous immunoglobulin in a pregnant patient with antiphospholipid syndrome: immunological changes associated with a successful outcome. Thromb Haemost 1994;71:741–747

71. Fishman P, Falach Vaknine E, Zigelman R, et al. Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest1993;21:1834–1837.

72. Gordon C, Kilby MD. Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Lupus 1998;7:429–433.

73. Triolo G, Ferrante A, Ciccia F, et al.

Corresponding Author

Dr Arata Kumar Swain

MD, FCCM, FCCS, Assistant Professor

Department of Anaesthesiology &Critical care, VIMSAR, Burla